This is a summary of the European public assessment report (EPAR) for Procysbi. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Procysbi.
For practical information about using Procysbi, patients should read the package leaflet or contact their doctor or pharmacist.
Procysbi : EPAR - Summary for the public (PDF/69.59 KB)
First published: 03/10/2013
Last updated: 03/10/2013
Procysbi : EPAR - Risk management plan summary (PDF/172.29 KB)
First published: 08/09/2022
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Chiesi Farmaceutici S.p.A
|Date of issue of marketing authorisation valid throughout the European Union||
Via Palermo 26/A
17/08/2022 Procysbi - EMEA/H/C/002465 - X/0035
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Other alimentary tract and metabolism products
Procysbi is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.